Screened α-Helix Peptide Inhibitor toward SARS-CoV-2 by Blocking a Prion-like Domain in the Receptor Binding Domain

Shang Wu; Limin Zhang; Weizhi Wang

doi:10.1021/acs.analchem.2c02223

Screened α-Helix Peptide Inhibitor toward SARS-CoV-2 by Blocking a Prion-like Domain in the Receptor Binding Domain

Anal Chem. 2022 Aug 23;94(33):11464-11469. doi: 10.1021/acs.analchem.2c02223. Epub 2022 Jul 11.

Authors

Shang Wu¹, Limin Zhang¹, Weizhi Wang¹

Affiliation

¹ Key Laboratory of Medical Molecule Science and Pharmaceutics Engineering, Ministry of Industry and Information Technology, Key Laboratory of Cluster Science of Ministry of Education, Beijing Key Laboratory of Photoelectronic/Electro-photonic Conversion Materials, School of Chemistry and Chemical Engineering, Institute of Engineering Medicine, Beijing Institute of Technology, Beijing 100081, PR China.

PMID: 35816660
DOI: 10.1021/acs.analchem.2c02223

Abstract

A new peptide inhibitor was designed and optimized from an α-helix-rich peptide library specifically toward the critical prion-like domain (PLD) of SARS-CoV-2. It compactly blocked the S1 protein and potently neutralized the pseudovirus which shows promising potential for prophylactic and treatment of COVID-19.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

COVID-19 Drug Treatment*
Humans
Peptides / chemistry
Prions*
Protein Binding
Protein Conformation, alpha-Helical
SARS-CoV-2
Spike Glycoprotein, Coronavirus / chemistry

Substances

Peptides
Prions
Spike Glycoprotein, Coronavirus
spike protein, SARS-CoV-2